Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
Clinical trial NCT04676412 · COMPLETED
Trial details
- NCT number
- NCT04676412
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-23
- Primary completion
- 2021-05-19
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.